The evolving landscape of rare tumour molecular characterisation
Continued collaboration to identify new molecular targets and treatments can build on existing success
Sinonasal cancer: whole-exome sequencing reveals potential therapeutic targets
Results from a study suggest that some existing inhibitors may benefit all subtypes of these rare malignancies, which currently lack effective treatments
Access to high-quality care for sarcomas is still unequal worldwide
Delays and poor patient journey are reported in resource-constrained countries, while awareness campaigns and healthcare service reorganisation have improved rare cancer management in more developed areas
Encouraging results validate PARP7 and TGFβ1 as potential targets for immunotherapy
Safety and biomarker status data of the PARP7 inhibitor RBN-2397 and the IgG4 monoclonal antibody SRK-181 presented at the ESMO TAT Congress 2023
Promising results for an FGFR 1–3 inhibitor in molecularly altered tumours
CPL304110 shows acceptable toxicity and early signs of activity in heavily pre-treated patients with advanced solid malignancies
New tools and methods are discussed for optimising investigation of precision therapeutics
Results of extensive genomic profiling and a Time-to-Event Continual Reassessment Method show some promise in investigating new treatments and targets in early-phase trials, despite not being ready for routine research
NGS – a weapon in molecular pathology?
Next generation sequencing has revolutionised cancer management, but has also raised some issues that have yet to be addressed
Early phase cancer research – ready for a change?
New recommendations of the MDICT Taskforce highlight the need to rethink how research studies are conducted and of multi-stakeholder collaboration
Is ATR inhibition a potential new treatment for rare gynaecological cancers?
Ceralasertib, alone or in combination with PARP inhibition, showed signs of clinical efficacy in patients with relapsed ovarian and endometrial clear cell carcinomas (CCC), for whom effective treatment options are currently lacking
Ovarian cancer: updated phase III data provide reassurance for the use of PARPi as maintenance therapy
Sustained benefit of PARPi treatment may help to put the recent concerns on how and when to use these agents in women into context